Aclaris Therapeutics, Inc.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $7.8M | $18.7M | $31.2M | $29.8M | $6.8M | $6.5M | $4.2M | $6.2M |
| Cost of Revenue | $2.1M | $2.8M | $3.4M | $4.0M | $4.7M | $5.1M | $4.1M | $4.3M |
| Gross Profit | $5.7M | $15.9M | $27.8M | $25.7M | $2.0M | $1.3M | $172.0K | $3.2M |
| Gross Margin | 73.3% | 85.1% | 89.0% | 86.5% | 30.3% | 20.8% | 4.1% | 52.7% |
| Operating Expenses | ||||||||
| Research & Development | $52.6M | $33.6M | $98.4M | $77.8M | $43.8M | $29.3M | $64.2M | $60.8M |
| SG&A Expense | $22.0M | $22.2M | $32.4M | $25.1M | $23.6M | $20.5M | $27.8M | $25.8M |
| Operating Income | $-76.4M | $-141.9M | $-97.4M | $-89.9M | $-89.7M | $-50.9M | $-111.1M | $-84.8M |
| Operating Margin | -975.9% | -758.2% | -311.6% | -302.0% | -1,327.1% | -785.4% | -2,627.3% | -1,378.3% |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | $-64.9M | $-132.1M | $-88.8M | $-86.9M | $-90.9M | $-51.3M | $-113.5M | $-82.1M |
| Income Tax Expense | — | — | $-367.0K | — | — | $-182.0K | — | — |
| Net Income | $-64.9M | $-132.1M | $-88.5M | $-86.9M | $-90.9M | $-51.0M | $-161.4M | $-132.7M |
| Net Margin | -829.6% | -705.5% | -283.1% | -292.1% | -1,344.0% | -787.0% | -3,817.2% | -2,158.0% |
| EPS (Basic) | $-0.53 | $-1.71 | $-1.27 | $-1.33 | $-1.60 | $-1.20 | $-3.90 | $-4.03 |
| EPS (Diluted) | $-0.53 | $-1.71 | $-1.27 | $-1.33 | $-1.60 | $-1.20 | $-3.90 | $-4.03 |
| Shares Outstanding (Basic) | 122.6M | 77.3M | 69.8M | 65.2M | 56.7M | 42.5M | 41.3M | 41.2M |
| Shares Outstanding (Diluted) | 122.6M | 77.3M | 69.8M | 65.2M | 56.7M | 42.5M | 41.3M | 41.2M |
| Dividends Per Share | — | — | — | — | — | — | — | — |